| Name | Trilaciclib hydrochloride |
| Description | Trilaciclib hydrochloride (G1T28 hydrochloride) is an inhibitor of CDK4/6 (IC50s: 1 nM and 4 nM for CDK4 and CDK6). |
| In vitro | Incubation with Trilaciclib hydrochloride (G1T28) for 24 hours can induce a strong G1 cell cycle arrest (time=0). Cells have re-entered the cell cycle and demonstrate cell-cycle kinetics similar to untreated control cells By 16 hours after Trilaciclib hydrochloride washout. These results demonstrate that Trilaciclib hydrochloride causes a transient, and reversible G1 arrest. A transient Trilaciclib hydrochloride-mediated G1 cell-cycle arrest in CDK4/6-sensitive cells decreases the in vitro toxicity of a variety of commonly used cytotoxic chemotherapy agents associated with myelosuppression. |
| In vivo | G1T28 inhibits the phosphorylation of RB and induces an exclusive, reversible G1 arrest.n vivo, G1T28 reversibly and in a dose-dependent manner, regulates the proliferation of HSPCs.Pretreatment of mice with oral G1T28 allows for the faster recovery of CBCs following chemotherapy treatment.Likewise, oral G1T28 does not protect RB-deficient tumors from chemotherapy but adds to the antitumor effect.Although this effect was found in athymic mice that lack T lymphocytes, it is still possible that the enhanced efficacy is due to preservation of other immune cell types such as natural killer cells. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : Insoluble
H2O : 10 mM, Sonication is recommended.
|
| Keywords | Trilaciclib Hydrochloride | Trilaciclib hydrochloride | Trilaciclib | Inhibitor | inhibit | G1T28 Hydrochloride | G1T28 | Cyclin dependent kinase | CDK6/CyclinD3 | cdk6/cyclin D3 | Cdk4/cyclin D1 | CDK4/Cyc D1 | CDK |
| Inhibitors Related | Ribociclib | Ro-3306 | Abemaciclib | Rafoxanide | AT7519 | Palbociclib monohydrochloride | CASIN | GW 441756 | Sodium Oxamate | Seliciclib | Abemaciclib methanesulfonate | Dinaciclib |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Inhibitor Library | FDA-Approved Kinase Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
United States
